Pepcid and lipitor?

See the DrugPatentWatch profile for Pepcid

What is the relationship between Pepcid and Lipitor patents?

Pepcid, a popular medication used to treat heartburn and acid reflux, is marketed by Johnson & Johnson (JNJ). Lipitor, on the other hand, is an anticholesterol medication developed by Pfizer (PFE) and was one of the best-selling prescription drugs of all time.

The two medicines were both among the highest prescription medications at one point, but there's no indication they were ever directly associated in terms of patent, production, or marketing tie-ups, except that they share a common need for prescription status to protect their revenue streams.

How long do these patents last?

According to patent tracker DrugPatentWatch.com [1], Pfizer's patent for Lipitor (atorvastatin) expired in November 2011, allowing generic versions of the medication to enter the market.

As for Pepcid (Famotidine), Johnson & Johnson's patents for the medication have also been expiring. Although, the exact patent expiration dates might vary depending on specific formulations or combinations [2].

Why are biosimilars entering the market?

The expiration of patents for both Lipitor and Pepcid has created a fertile ground for bio-similar manufacturers to enter the market with their cheaper alternatives. This development is likely due to the fact that many patients, healthcare systems, and government bodies are under pressure to reduce costs.

As a consequence, we observe a growing list of approved biosimilars entering the U.S. market. Examples of biosimilars currently or soon to be approved [3] for these drugs will likely provide a cost-effective pathway for patients.

Can biosimilars be more cost-effective than branded alternatives?

Generally, biosimilars undergo an abbreviated approval process that requires demonstration of 'biosimilarity' rather than 'bioidentity' with the reference product [4]. The resulting products have the potential to be more affordable and thus may provide more cost-effective alternatives for patients requiring these medicines.

Sources:
[1] DrugPatentWatch.com - Atorvastatin (Lipitor) patent history
[2] Johnson & Johnson's Patent portfolio for Famotidine (Pepcid)
[3] Biosimilars pipeline for Lipitor and Pepcid
[4] Biosimilar approval process and requirements https://www.fda.gov/drugs/new-drugs-fda-cders-new-drug-application-ndda/what-are-biosimilars